Free Trial
NASDAQ:TECH

Bio-Techne (TECH) Stock Price, News & Analysis

Bio-Techne logo
$71.28 +0.23 (+0.32%)
(As of 11/22/2024 ET)

About Bio-Techne Stock (NASDAQ:TECH)

Key Stats

Today's Range
$70.61
$72.41
50-Day Range
$66.37
$80.36
52-Week Range
$61.16
$85.57
Volume
620,615 shs
Average Volume
1.23 million shs
Market Capitalization
$11.33 billion
P/E Ratio
75.83
Dividend Yield
0.45%
Price Target
$81.78
Consensus Rating
Moderate Buy

Company Overview

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Bio-Techne Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
97th Percentile Overall Score

TECH MarketRank™: 

Bio-Techne scored higher than 97% of companies evaluated by MarketBeat, and ranked 45th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bio-Techne has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Bio-Techne has only been the subject of 2 research reports in the past 90 days.

  • Read more about Bio-Techne's stock forecast and price target.
  • Earnings Growth

    Earnings for Bio-Techne are expected to grow by 20.24% in the coming year, from $1.68 to $2.02 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bio-Techne is 75.83, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 117.37.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bio-Techne is 75.83, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 77.93.

  • Price to Earnings Growth Ratio

    Bio-Techne has a PEG Ratio of 5.19. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Bio-Techne has a P/B Ratio of 5.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Bio-Techne's valuation and earnings.
  • Percentage of Shares Shorted

    2.00% of the outstanding shares of Bio-Techne have been sold short.
  • Short Interest Ratio / Days to Cover

    Bio-Techne has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bio-Techne has recently decreased by 11.94%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Bio-Techne has a dividend yield of 0.45%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Bio-Techne does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Bio-Techne is 34.04%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Bio-Techne will have a dividend payout ratio of 15.84% next year. This indicates that Bio-Techne will be able to sustain or increase its dividend.

  • Read more about Bio-Techne's dividend.
  • Percentage of Shares Shorted

    2.00% of the outstanding shares of Bio-Techne have been sold short.
  • Short Interest Ratio / Days to Cover

    Bio-Techne has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bio-Techne has recently decreased by 11.94%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Bio-Techne has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for Bio-Techne this week, compared to 7 articles on an average week.
  • Search Interest

    3 people have searched for TECH on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Bio-Techne to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bio-Techne insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.90% of the stock of Bio-Techne is held by insiders.

  • Percentage Held by Institutions

    98.95% of the stock of Bio-Techne is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bio-Techne's insider trading history.
Receive TECH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.

TECH Stock News Headlines

Download Our Tesla Ebook For Free
Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.
Bio-Techne announces partnership with Leader Life Sciences
Bio-Techne, ALZpath announce strategic partnership
See More Headlines

TECH Stock Analysis - Frequently Asked Questions

Bio-Techne's stock was trading at $77.16 at the beginning of 2024. Since then, TECH shares have decreased by 7.6% and is now trading at $71.28.
View the best growth stocks for 2024 here
.

Bio-Techne Co. (NASDAQ:TECH) posted its quarterly earnings data on Wednesday, October, 30th. The biotechnology company reported $0.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.04. Bio-Techne's revenue for the quarter was up 4.5% compared to the same quarter last year.

Bio-Techne's stock split on the morning of Wednesday, November 30th 2022. The 4-1 split was announced on Tuesday, November 1st 2022. The newly created shares were distributed to shareholders after the market closes on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

Bio-Techne subsidiaries include these companies: MoGen Biotechnologies, Exosome Diagnostics, Quad Technologies, Advanced Cell Diagnostics, Space Import-Export Srl, Zephyrus Biosciences, Cliniqa, and others.

Bio-Techne's top institutional shareholders include State Street Corp (4.03%), Bamco Inc. NY (2.80%), Geode Capital Management LLC (2.46%) and DF Dent & Co. Inc. (2.08%). Insiders that own company stock include Charles R Kummeth, Roeland Nusse, Brenda S Furlow, Robert V Baumgartner and John L Higgins.
View institutional ownership trends
.

Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bio-Techne investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Netflix (NFLX).

Company Calendar

Ex-Dividend for 8/30 Dividend
8/19/2024
Dividend Payable
8/30/2024
Last Earnings
10/30/2024
Ex-Dividend for 11/22 Dividend
11/08/2024
Dividend Payable
11/22/2024
Today
11/23/2024
Next Earnings (Estimated)
2/06/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:TECH
CUSIP
87837710
Employees
3,100
Year Founded
1981

Price Target and Rating

Average Stock Price Target
$81.78
High Stock Price Target
$95.00
Low Stock Price Target
$65.00
Potential Upside/Downside
+14.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Net Income
$168.10 million
Pretax Margin
15.05%

Debt

Sales & Book Value

Annual Sales
$1.16 billion
Cash Flow
$2.32 per share
Book Value
$13.46 per share

Miscellaneous

Free Float
152,695,000
Market Cap
$11.33 billion
Optionable
Optionable
Beta
1.28

Social Links

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:TECH) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners